Created at	Source	Raw Value	Validated value
Dec. 4, 2021, midnight	oms	safety At day 0-7 after dose 1 and 2 adverse events;IgG to receptor binding site At the beginning of the study; day 21; day 35 and day 51 BAU/mL;IgG to nucleocapsid antigen At the beginning; day 21; day 35 and day 51 %;neutralizing antibody At the beginning; day 21; day 35 and day 51 %;IFN-gamma At the beginning; day 21; day 35 and day 51 SFU/10 million PBMCs	safety At day 0-7 after dose 1 and 2 adverse events;IgG to receptor binding site At the beginning of the study; day 21; day 35 and day 51 BAU/mL;IgG to nucleocapsid antigen At the beginning; day 21; day 35 and day 51 %;neutralizing antibody At the beginning; day 21; day 35 and day 51 %;IFN-gamma At the beginning; day 21; day 35 and day 51 SFU/10 million PBMCs
Oct. 7, 2021, 9:30 a.m.	oms	safety At day 0-7 after dose 1 and 2 adverse events;IgG to receptor binding site At the beginning of the study; day 21; day 35 and day 51 BAU/mL;IgG to nucleocapsid antigen At the beginning; day 21; day 35 and day 51 %;neutralizing antibody At the beginning; day 21; day 35 and day 51 %;INF-gamma At the beginning; day 21; day 35 and day 51 SFU/10 million PBMCs	safety At day 0-7 after dose 1 and 2 adverse events;IgG to receptor binding site At the beginning of the study; day 21; day 35 and day 51 BAU/mL;IgG to nucleocapsid antigen At the beginning; day 21; day 35 and day 51 %;neutralizing antibody At the beginning; day 21; day 35 and day 51 %;INF-gamma At the beginning; day 21; day 35 and day 51 SFU/10 million PBMCs